ANOTHER STUDY BRINGS MORE HOPE -- ALPHA SYNUCLEIN CLUMP REMOVAL

[jimcaster]

More ENCOURAGING news...

m.medicalxpress.com/news/20...

[Kia17]

Thanks for sharing.

"Our discovery clearly indicates that inhibition of USP13 is a strategic step to activate parkin and counteract alpha-synuclein de-ubiquitination, to increase toxic protein clearance" added Moussa. "Our next step is to develop a small molecule inhibitor of USP13 to be used in combination with nilotinib in order to maximize protein clearance in Parkinson's and other neurodegenerative diseases.Nilotinib is FDA approved for use in specific blood cancers.”

[ConnieD in reply to Kia17]

Hi Kia!! Correct me if I’m wrong but isn’t nilotinib in trial phases for Parkinson’s? I couldn’t open the attachment and do you know if some Drs allow PD patients to try it?

[Kia17 in reply to ConnieD]

Hi Connie ,Nilotinib is considered to be combined with the USP13 for the alpha-synucleun removal but none of them are in trial phase yet. Nilotinib is a medication being used for some special type of CML(Leukaemia) and I donot think any doctor dares to prescribe it for PD without being approved by the FDA for that purpose.

[ConnieD in reply to Kia17]

Thanks Kia for explaining and to Jim for sharing!!😊

[Kia17 in reply to ConnieD]

You’re welcome Connie.

[jimcaster in reply to ConnieD]

google.com/amp/s/parkinsons...

[MBAnderson in reply to ConnieD]

Connie, I've been taking Nilotinib since 11/1/16 and I know of only one doctor (in upstate New York) who has prescribed it, but he has since stopped. N is in phase II trials.

m.medicalxpress.com/news/20...

[ConnieD in reply to MBAnderson]

Interesting MB! What symptoms do you find it helpful for? When a drug is in phase 2 how much longer before it could possibly come to market? I know it has to go through phase 3 as well. Thanks, Connie

[MBAnderson in reply to ConnieD]

Connie,

I cannot attribute any benefit to it because my regime includes a lot of other stuff. However, I had my semiannual visit with my neurologist at the VA a couple weeks ago and he said I had improved since my previous visit and, assuming that is true, I would not attribute all the benefit to N.

There's no telling how long it takes to get to market.

Perhaps phase II trial will end in one year and then 6 to 12 months to publish the data, then 12 to 18 months to organize (secure all approvals) and raise the funding for phase III, which, including time for recruiting, could take 36 months to complete and publish the data then perhaps 18 to 24 months for FDA approval.

Best case scenario 7 years up to perhaps 10 years.

[ConnieD in reply to MBAnderson]

Thanks that sure is a long time! I’m glad you are able to use it, keep it up you’re doing something right that’s for sure!!😊

[Kia17 in reply to MBAnderson]

Thank you . I didn’t know that.

[kalyan48 in reply to Kia17]

correct me if I am wrong , but isn't MANNITOL supposed to clear alpha-synuclein

[Kia17 in reply to kalyan48]

The study is targeting different substances than Mannitol. It doesn’t discredit Mannitol’s functionality.

[kalyan48 in reply to Kia17]

Thanks

[Xenos]

Sounds really promising.

Thanks for sharing this.

[MBAnderson]

Apparently, Moussa et. al. are not resting on their laurels, nor has forsaken N.